Prucalopride Shortage: What Providers and Prescribers Need to Know in 2026

Prucalopride (Motegrity) has been a valuable addition to the toolkit for managing chronic idiopathic constipation (CIC) since its FDA approval in December 2018. However, availability challenges — ranging from high brand prices and insurance step therapy requirements to localized pharmacy stock-outs — have consistently made it difficult for some patients to access. This clinical update summarizes the current access landscape and key considerations for prescribers in 2026.

FDA Status: No Official Shortage, But Continued Localized Access Issues

Prucalopride is not listed on the FDA's current drug shortage database. However, localized pharmacy stock-outs remain common for multiple reasons: the ongoing brand-to-generic transition, low baseline stocking levels at many pharmacies, and uneven uptake of the generic across pharmacy chains and independent pharmacies.

Providers should be aware that a patient's inability to fill prucalopride may not reflect a systemic manufacturing problem but rather a localized stocking issue that can often be resolved by searching a different pharmacy or requesting a special order.

The 2025 Generic Launch: Clinical and Access Implications

ANI Pharmaceuticals received FDA approval for the first generic prucalopride in January 2025, launching with 180-day competitive generic therapy (CGT) exclusivity. The FDA's approval was supported by bioequivalence data to brand-name Motegrity. For patients, this reduced the cash price from $550–$735/month (brand) to $26–$40/month with GoodRx or similar discount programs.

From a prescribing standpoint, providers can now write for "prucalopride" generically, which allows pharmacies to dispense whatever formulation they carry (brand or generic). This flexibility can help reduce access barriers when a patient's regular pharmacy is out of one formulation.

Insurance Landscape: Prior Authorization and Step Therapy

Prucalopride (especially brand-name Motegrity) is classified as a non-preferred or Tier 3–4 drug on many commercial formularies. Most major payers — including Cigna, UnitedHealthcare, and some Blue Cross plans — require prior authorization, and many require documented failure of preferred agents first.

Common step therapy requirements include:

• Trial and inadequate response to linaclotide (Linzess) — the most commonly preferred GI agent on formularies
• Some plans also require prior trial of plecanatide (Trulance)
• Documentation of CIC diagnosis lasting at least 3 months with failed OTC laxative therapy

Medicare Part D coverage varies significantly by plan — many Part D formularies still do not list prucalopride. Encourage patients without commercial insurance to check their specific plan's formulary and consider GoodRx-discounted generic if no coverage is available.

Clinical Positioning: Where Prucalopride Fits in 2026 CIC Management

American Gastroenterological Association (AGA) and ACG guidelines strongly recommend prucalopride, linaclotide, and plecanatide as options for patients with CIC who have not responded to OTC agents. Prucalopride's unique mechanism — selective 5-HT4 receptor agonism — makes it particularly useful when:

• Patients have failed or cannot tolerate secretagogues (linaclotide, plecanatide) due to diarrhea
• The primary issue is slow colonic transit (slow-transit constipation) where prokinetic effect is most needed
• Patients have both constipation and suspected gastroparesis (off-label use)

Key Safety Reminders: Suicidality Warning

Although a causal relationship has not been firmly established, prucalopride's prescribing information includes a warning for suicidal ideation and behavior based on clinical trial and post-marketing data. Providers should:

• Counsel patients to report unusual changes in mood, depression, or suicidal thoughts
• Monitor patients with pre-existing depression or psychiatric history more closely
• Instruct patients to discontinue and contact their provider immediately if suicidal thoughts emerge

Renal Dosing Adjustments

Prucalopride is primarily eliminated renally. Dose adjustments are required for elderly patients and those with moderate-to-severe renal impairment. Prucalopride is contraindicated in patients with end-stage renal disease (ESRD) requiring dialysis. For patients with CrCl < 30 mL/min, a reduced dose of 1 mg daily is recommended.

Supporting Patients Who Can't Find Prucalopride

When patients call your office saying they cannot fill their prucalopride prescription, encourage them to use medfinder — a service that calls pharmacies near patients to find which ones have the medication in stock. This can save hours of patient frustration and reduce unnecessary callbacks to your office.

For patients facing prolonged access challenges, consider a temporary bridge with an alternative agent (linaclotide or lubiprostone), and ensure any prior authorization documentation is current so coverage doesn't lapse.

Clinical Alternatives to Prucalopride

For a detailed comparison of CIC medications — including mechanism, dosing, and side effect profiles — see: Alternatives to Prucalopride If You Can't Fill Your Prescription. All four FDA-approved CIC medications (prucalopride, linaclotide, lubiprostone, plecanatide) are strongly recommended by gastroenterology guidelines for patients who fail OTC therapies.